Prospect: information for the patient
Alfuzosin Viatris 10 mg prolonged-release tablets EFG
Alfuzosin hydrochloride
For adult men
Read this prospect carefully before starting to take this medicine, because it contains important information for you.
1. What is Alfuzosin Viatris and what it is used for.
2. What you need to know before starting to take Alfuzosin Viatris.
3. How to take Alfuzosin Viatris.
4. Possible adverse effects.
5. Storage of Alfuzosin Viatris.
6. Contents of the package and additional information
AlfuzosinViatris contains the active ingredient alfuzosin hydrochloride, whichbelongs to a group of medicines called alpha-adrenergic receptor antagonists or alpha-blockers.
Alfuzosin Viatris is used to treat symptoms, from moderate to severe, caused by an enlarged prostate, also known as benign prostatic hyperplasia(non-cancerous). The prostate gland is located below the bladder surrounding the urethra, the tube that carries urine out of the body. If the prostate gland becomes enlarged, it exerts pressure on the urethra making it smaller.The enlargement of the prostate gland can cause urinary problems such as frequent urination and difficulty urinating, especially at night.
Alpha-blockers relax the muscles of the prostate and the bladder neck. This allows urine to flow out of the bladder more easily..
In some patients with benign prostatic hyperplasia, the prostate gland becomes so enlarged that it blocks the flow of urine completely. This is calledacute urinary retention.This is very painful and you may need to stay in the hospital for a short time. A thin and flexible tube (catheter) is inserted into the bladder. This drains the urine and relieves the pain. Alfuzosin may be used to help urine flow again.
Do not take Alfuzosina Viatris:
Do not take this medication if any of the above applies to you. If you are unsure, speak with your doctor or pharmacist before taking alfuzosina.
Warnings and precautions:
Consult your doctor or pharmacist before starting to take Alfuzosina Viatris..
When taking this medication, you may experience a sudden drop in blood pressure when standing up (you may feel dizziness, fatigue, weakness, or sweating), especially in the first hours after taking Alfuzosina Viatris. If you experience a drop in blood pressure, stay with your legs and feet elevated until the symptoms disappear. Usually, these effects last a short time and usually appear at the beginning of treatment. Normally, it is not necessary to interrupt treatment.Inform your doctor as they may decide to adjust your dose.
In case of an erection (often painful), not related to sexual activity, that persists for more than 4 hours, contact a doctor or go to the hospital immediately as you may need treatment.See the section below“Possible side effects”.
If you need to undergo eye surgery for cataracts (opacity of the crystalline lens), please inform your ophthalmologist before the surgery if you are taking or have taken Alfuzosina Viatris. This is because Alfuzosina Viatris may cause complications during the surgery, which can be taken into account and controlled by your ophthalmologist if you have been informed in advance.
Children and adolescents:
Alfuzosina Viatris is not recommended for use in children and adolescents (patients under 16 years of age).
Taking Alfuzosina Viatris with other medications:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
Do not take Alfuzosina Viatris if you are taking other medications belonging to the group known as alpha-blockers, such as doxazosina, indoramina, terazosina, prazosina, or tamsulosina.
Alfuzosina Viatris may modify the action of other medications.Inform your doctor or pharmacist if you are taking any of the following medications:
If you are to undergo surgery that requires general anesthesia, inform your doctor or hospital staff that you are taking this medication. Your doctor may recommend that you stop taking this medication 24 hours before surgery to prevent the risk of changes in blood pressure.
Pregnancy and breastfeeding:
Alfuzosina Viatris is only indicated for use in men.
Alfuzosina with food and drinks:
Take alfuzosina after meals.
Driving and operating machinery:
Especially at the beginning of treatment, Alfuzosina Viatris may cause dizziness, vertigo, or weakness. Do not drive, operate machinery, or perform hazardous tasks until you know how your body reacts to this medication.
Alfuzosina Viatris contains lactose:
This medication contains lactose. If your doctor has indicated that you have a certain sugar intolerance, consult with them before taking this medication.
How much to take
Benign Prostatic Hyperplasia
Acute Urinary Retention
Swallow the tablet whole with sufficient liquid. Do not crush, pulverize, or chew the tablets as excessive amounts of the active ingredient alfuzosin may enter your body too quickly. This could increase the risk of adverse effects.
If you have kidney problems
If you have moderate or severe kidney disease, your doctor may recommend starting with a lower dose of alfuzosin. If a lower dose does not work, your doctor may recommend taking one tablet (10 mg of alfuzosin) once a day. Take the tablet after dinner.
If you take more Alfuzosina Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you take large amounts of Alfuzosina Viatris, you may experience a sudden drop in blood pressure and feel dizzy or even faint. If you start to feel dizzy, sit or lie down until you feel better. If symptoms do not subside, call your doctor as this drop in blood pressure should be treated in a hospital.Do not drive yourself to the hospital.
If you forgot to take Alfuzosina Viatris
Do not take a double dose to compensate for the missed doses as it may cause a sudden drop in blood pressure. Take the next tablet as instructed.
If you interrupt treatment with Alfuzosina Viatris
You should not interrupt or stop taking alfuzosin without consulting your doctor first.
If you want to interrupt treatment or have any other questions about the use of this medication, ask your doctor or pharmacist.
Use in children
Alfuzosin is not indicated for use in children.
If you experience any of the following side effects, stop taking this medicine, consult your doctor or go to the nearest hospital emergency department immediately:
Other possible side effects
Frequent(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 100 people):
Unknown(frequency cannot be estimated from available data):
If you are to undergo eye surgery due to cataracts (opacity of the crystalline lens of the eye) and are already taking or have taken alfuzosin in the past, the pupil may dilate slightly and the iris (the colored part of the eye) may become flaccid during the procedure. This only occurs during the operation and it is essential that the ophthalmologist is informed as it may be necessary to perform the operation differently (see “Warnings and precautions”).
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not store above a temperature of30°C.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister and on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment
Composition of Alfuzosin Viatris
The active ingredient is alfuzosin hydrochloride. Each prolonged-release tablet contains 10 mg of alfuzosin hydrochloride.
The other components are: lactose monohydrate, hypromellose, povidone, and magnesium stearate.
Appearance of the product and contents of the package
Alfuzosin Viatris 10 mg are prolonged-release white, round, beveled-edge tablets without coating.
They are available in blisters of 10, 20, 30, 50, 60, 90, and 100 tablets and in perforated single-dose blisters of 30 and 60 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible manufacturer:
Mylan Hungary Kft.
H-2900 Komárom
Mylan utca 1
Hungary
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medication is authorized in the member states of the European Economic Area with the following names:
DenmarkLafunomyl 10 mg
AustriaAlfuzosin 'Arcana' 10 mg Retardtabletten
BelgiumAlfuzosine Mylan 10 mg
Czech RepublicAlfuzosin Mylan 10 mg
FinlandLafunomyl 10 mg
SpainAlfuzosina Viatris 10 mg prolonged-release tablets EFG
HungaryAlfugen 10 mg
IrelandXatger 10 mg prolonged-release tablet
ItalyAlfuzosina Mylan 10 mg
NetherlandsAlfuzosine HCl Retard Mylan 10 mg, tablets with regulated release
PolandAlugen 10 mg
PortugalAlfuzosina Mylan 10 mg
SwedenLafunomyl 10 mg
SlovakiaAlfuzosin Mylan 10 mg
United Kingdom (Northern Ireland)Taurazil SR 10 mg Tablets
Last review date of this leaflet: December 2021
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.